Blaas- en urinewegentumoren
TAR-210 MoonRISE-3
A phase 3, randomized study evaluating the efficacy and safety of TAR-210 Erdafitinib intravesical delivery system vs. intravesical chemotherapy in participants with High-risk Non-muscle-invasive Bladder Cancer with susceptible FGFR alterations who received intravesical BCG
- Inclusion criteria: Papillary-only HR-NMIBC (defined as HG Ta or any T1, no CIS), susceptible FGFR mutation (urine of tissue), recurrence within 12 months after BCG
- Exclusion criteria: Presence of CIS, UC or histological variant at any site outside of the urinary bladder, N+ and/or M+ per BICR of CT/MR Urography
- Investigator: prof. dr. Ben Van Cleynenbreugel
- Sub-investigator (Urology): dr. Carl Van Haute
- More information: NCT06919965
EFFORT Trial
Phase II prospective trial to evaluate the impact of 18FFDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and adapting the treatment accordingly.
- Inclusion criteria: Patients diagnosed with muscle invasive bladder cancer without distant metastasis on conventional imaging (CT chest, abdomen and pelvic MRI) and who are candidates for neoadjuvant chemotherapy and radical curative treatment.
- Local site Principal Investigator (Urology): prof. dr. Maarten Albersen
- Sub-investigator (Nuclear Medicine): prof. dr. Karolien Goffin
- Sub-investigator (Radiotherapy): prof. dr. Gert De Meerleer
- More information: dr. Loïc Baekelandt (PhD) via loic.baekelandt@uzleuven.be or 016 344722
SINCERE Registry
Effect of a single instillation of Mitomycin C on the intravesical recurrence rate after ureteroscopy for Upper Tract Urothelial Carcinoma: A prospective, multicenter registry study.
- Inclusion criteria: All patients ≥ 18 years old with clinically non-metastatic UTUC planned for URS, either as a diagnostic or as treatment, followed by a SI-MMC (or any equivalent) are eligible for this study.
- Local site Principal Investigator: dr. Carl Van Haute
- More information: NCT05731622
Niertumoren
Er zijn momenteel geen studies beschikbaar.
Penistumoren
Er zijn momenteel geen studies beschikbaar.
Prostaattumoren
Intermittent Androgen Deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE)
- Inclusion criteria: mHSPC on ADT + ARPI for 6-12M and presenting with PSA ≤ 0.2ng/mL
- Exclusion criteria: M1a on PSMA PET/MRI for whom RT and 2-3Y of hormone therapy is planned
- Investigator: prof. dr. Wouter Everaerts
- Sub-investigator: prof. dr. Steven Joniau
- More information: NCT05974774
Testistumoren
Er zijn momenteel geen studies beschikbaar.
Urinaire incontinentie
NEMISIS
Sacral neuromodulation as treatment for voiding dysfunction in multiple sclerosis patients.
- Inclusion criteria: Diagnosis of Multiple Sclerosis according the McDonald criteria, stable relapsing remitting MS, EDSS 0-6, storage LUTD with Urgency Frequency or Urgency Urinary Incontinence.
- Local site Principal Investigator: prof. dr. Frank Van der Aa
- Sub-investigator (Urology): dr. Lisa Moris
- More information: urologie.trial@uzleuven.be
Urineweg-infecties
MINUS Trial
Multicentric study on Infections of the Urinary tract after Stent removal
- Inclusion criteria: Patients, 18 years of age and older who receive a ureteral stent during any endoscopic procedure will be approached to participate in the study
- Local site Principal Investigator: dr. Carl Van Haute
- Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugel
- More information: NCT05329883
Zelfkatheterisatie
EVA studie
Study of Colopast catheter selection criteria at start of self-catheterisation
- Inclusion criteria: patients with neurogenic or non-neurogenic bladder issues, justifying the implementation of intermittent self-catheterisation (ISC) to clean out the bladder, for at least 6 months
- Local site Principal Investigator: prof. dr. Frank Van Der Aa
- Sub-investigator: dr. Lisa Moris
- More information: NCT05065255
Questions
For more information, please contact trial urology.
- Email: urologie.trial@uzleuven.be
- Phone: +3216348345